UBS Group
ENSC icon

UBS Group’s Ensysce Biosciences ENSC Stock Holding History

UBS Group’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.73K Buy
8,791
+8,691
+8,691% +$5.51K ﹤0.01% 8893
2025
Q4 		$92 Sell
100
-700
-88% -$1.3K ﹤0.01% 10200
2025
Q3 		$1.9K Buy
800
+446
+126% +$959 ﹤0.01% 9261
2025
Q2 		$789 Sell
354
-954
-73% -$2.19K ﹤0.01% 9739
2025
Q1 		$3.35K Buy
1,308
+713
+120% +$4.13K ﹤0.01% 9225
2024
Q4 		$4.84K Sell
595
-6,917
-92% -$47.7K ﹤0.01% 8720
2024
Q3 		$27K Buy
+7,512
New +$45.6K ﹤0.01% 7175
2024
Q2 		– Sell
-841
Closed -$9.96K – 9658
2024
Q1 		$9.96K Buy
+841
New +$13.3K ﹤0.01% 7255
2023
Q4 		– Sell
-10
Closed -$161 – 9175
2023
Q3 		$203 Buy
+10
New +$284 ﹤0.01% 8706
2023
Q2 		– Sell
-170
Closed -$12.4K – 9091
2023
Q1 		$12.4K Buy
170
+93
+121% +$10.7K ﹤0.01% 7451
2022
Q4 		$10.4K Buy
77
+63
+450% +$29.9K ﹤0.01% 8514
2022
Q3 		$11K Buy
14
+9
+180% +$14.7K ﹤0.01% 8284
2022
Q2 		$15K Buy
5
+3
+150% +$8.4K ﹤0.01% 7281
2022
Q1 		$9K Sell
2
-1
-33% -$6.61K ﹤0.01% 8541
2021
Q4 		$46K Buy
+3
New +$28.3K ﹤0.01% 6982

Other funds holding ENSC

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TIAM2
Tru Independence Asset Management 2 Portland, Oregon $163M AUM 18.06% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS Group's ENSC Position: Q1 2026 in Review

UBS Group increased its Ensysce Biosciences (ENSC) stake by 8,691% in Q1 2026, buying an estimated $5.51K and bringing the position to 8,791 shares worth $4.73K. The position accounts for ﹤0.01% of the portfolio, ranked #8893.

UBS Group first reported a position in ENSC in Q4 2021 and has held it in 15 quarters since. The position peaked at $46K in Q4 2021. 15 funds tracked by Wall St. Rank hold ENSC as of Q1 2026.

  • UBS Group held 8,791 shares of Ensysce Biosciences worth $4.73K as of Q1 2026.
  • UBS Group bought 8,691 Ensysce Biosciences shares in Q1 2026, an estimated $5.51K.
  • Ensysce Biosciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8893 holding.
  • UBS Group first reported a position in Ensysce Biosciences in Q4 2021 and has held it in 15 quarters since.
  • UBS Group's Ensysce Biosciences position peaked at $46K in Q4 2021.
  • 15 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.